Regencell Investors Face June 23 Deadline in Securities Lawsuit

The legal action, spearheaded by Faruqi & Faruqi, LLP, alleges that Regencell Bioscience Holdings Limited failed to disclose critical risks associated with its ordinary shares. According to the complaint, the company concealed its susceptibility to market volatility and the subsequent danger of government enforcement. These omissions allegedly left investors exposed to significant financial harm when the reality of the company's position surfaced.

The situation shifted on October 31, 2025, when Regencell revealed in an SEC filing that it had received a subpoena from the U.S. Department of Justice. The investigation focuses on trading activities in the company's shares. Following this disclosure, Regencell’s stock price dropped 18.56%, closing at $13.56 per share on November 3, 2025. The company has since acknowledged that it faces potential fines, penalties, and mounting legal expenses that could exceed its existing insurance coverage.

Investors who incurred losses during the specified class period are encouraged to evaluate their legal options. While the court will appoint a lead plaintiff to represent the class, individual shareholders are not required to take active roles to remain eligible for potential recovery. Those seeking further information or wishing to discuss the case may contact partner Josh Wilson at 877-247-4292.